Gynesonics Announces Expert Group of European Gynecologic Surgeons Publishes Consensus on the Broad Use of the Sonata Technology in a New Treatment Strategy for Symptomatic Fibroids
Redwood City, CA, August 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today a group of 12 surgeons from multiple fibroid treatment centers in Germany, Austria and Switzerland have published a review of symptomatic fibroid treatments, and recommended a treatment algorithm based on fibroid type and location.1 In this algorithm, Gynesonics’ Sonata® System was placed as the primary treatment procedure for 4 of 9 fibroids types (FIGO types 2, 3, 4 and 2-5) encompassing over 60% of fibroid occurrence. In the remaining applicable fibroids (FIGO types 1, 5 and 6), the recommendation was that Sonata should be considered for certain common scenarios such as larger and deeper fibroids that may be more difficult to treat surgically, including staged treatments or for women that have multiple fibroids. This supports utilizing Sonata as a treatment for more than 80% of fibroid types. This recommendation came shortly before The American College of Obstetricians and Gynecologists (ACOG) published new guidelines also supporting the use of Transcervical Radiofrequency Ablation (TRFA) for the treatment of symptomatic fibroids. Sonata is the only commercially available TRFA system. This expert consensus led to a new recommended treatment algorithm for each fibroid type:
“When we began evaluating transcervical radiofrequency fibroid ablation (TRFA) using Sonata, we quickly learned that this technique, a completely incision free procedure, would be applicable for a wide range of fibroid types and patients,” said Prof. Dr. med Thomas Römer, Evangelisches Klinikum Köln-Weyertal, in Cologne, Germany. “This creates the opportunity for many more women to take advantage of the extremely fast recovery and durable results. This procedure can be placed in the operating theatre workflow quickly and in a straightforward manner.”
The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wider range of fibroid types, sizes, and locations than hysteroscopic myomectomy. Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.
“This new fibroid treatment algorithm will be useful for physicians in the United States who are now evaluating where Sonata should be placed in their clinical protocols,” said Kelly Roy, MD, Arizona Gynecology Consultants, Assistant Program Director FMIGS Banner University Medical Center and Clinical Assistant Professor, University of Arizona College of Medicine-Phoenix. “This is an unprecedented opportunity to build on the clinical experience of these surgeons, who have performed over 1000 Sonata procedures in multiple, established fibroid treatment centers. This published experience will allow physicians to create a protocol more rapidly and confidently, including patient selection criteria, utilizing Sonata (TRFA). This review is aligned with the recent practice guidance by ACOG that recognizes the role of transcervical fibroid ablation as an important option for women in the treatment of symptomatic fibroids.2 Additionally, the Sonata System allows the surgeon to treat the most common types of myomas, which are not accessible by any other transcervical method, and therefore Sonata is the only fibroid ablation system noted in the ACOG guidelines that can avoid abdominal incisions.”
After reviewing published clinical results, including procedure time, recovery time, complication rate and reintervention rate, the authors found the TRFA procedure to be favorable in the majority of characteristics.
Related news
-
Synaptive Medical Announces Timothy J. Scannell as New Chair of Board of Directors
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of experience and expertise in the medical device industry. Prior to joining the Board at Synaptive, Mr. Scannell served as President and Chief Operating Officer of Stryker...
-
Synaptive Medical Welcomes Provincial Investment to Expand Manufacturing and R&D Activities
Synaptive Medical has received $900,000 in support from the Ontario government through the Ontario Together Fund. This funding will support Synaptive Medical’s $2.8 million project to expand manufacturing and research and development activities related to the company’s head-only Magnetic Resonance Imaging (MRI) system. The Synaptive MRI is a 0.5T system that was designed to overcome challenges such as accessibility in critical and acute cases like brain tumour and stroke, enabling healthcare professiona...
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
-
Best HIFU ultrasound facelift machine for medical aesthetic
Today, the medical aesthetic industry has developed to make people more comfortable and safe in their pursuit of beauty. Among the many medical aesthetic procedures available, the best HIFU machine professional is a popular one. It is based on high intensity focused ultrasound technology and provides amazing aesthetic results. This article will reveal the magic of HIFU in a number of sections. Bvlaser is a ODM face lift HIFU machine manufacturer, we have HIFU vaginal tightening machine for sale. Principles of...
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique in the medical aesthetic industry, is also very popular in the current medical aesthetic field. Bvlaser is the best...
Customer comments
No comments were found for Gynesonics Announces Expert Group of European Gynecologic Surgeons Publishes Consensus on the Broad Use of the Sonata Technology in a New Treatment Strategy for Symptomatic Fibroids. Be the first to comment!